



1 April 2020

Company Announcements Office  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

Dear Sir/Madam

### **MEDLAB COMPLETES ITS DEPRESSION TRIAL**

- Medlab completes and closes its depression trial being conducted at Queensland University of Technology (QUT).
- Pathology and Independent review expected in 3 months
- The investigative product, NRGBiotic™ has several patents and is available in Pharmacy and healthcare providers

Medlab Clinical Limited (ASX:MDC) is extremely pleased to announce the completion of the intervention stage of the QUT Depression trial using a product already in market, NRGBiotic™. NRGBiotic™ is a multi-patented probiotic available throughout Australian Pharmacies.

Further to the ASX announcement released on 19 November 2019, where the potential for early trial closure was indicated, the trial (n=150) has been closed at 120 patients due to a distinct trendline in the blinded trial data.

This trial was HREC approved by Queensland University of Technology, Office of Research Ethics and Integrity ([2017000186](#)), given a Federal Government Clinical Trial Number (CTN) and in accordance with CTN guidelines entered onto the Australian, New Zealand Clinical Trial Registry: <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372580&isReview=true>

In July 2018 Medlab announced the commencement of recruitment for the TGA approved Clinical Trial. It was a 150 participant study to follow on from previous trials investigating the use of NRGBiotic™ versus placebo as an adjuvant (used with) to an SSRI and or SNRI (common anti-depressant medications) for people diagnosed with depression that were getting little or no relief from standard medical treatment. This trial has received Government grants of \$75,000 attesting to the relevance of the trial and community needs.

Dr Sean Hall, CEO of MDC said, “personally in light of the COVID impact today, I am very pleased we have been able to fulfil our research duties with minimal interference to participants, and whilst the intervention stage is completed, the trial cohort will for the next 3 months focus on testing outcomes and an independent analysis of those results.”

Prof Luis Vitetta, Director of Medical Research at MDC, also added “the completion of a randomised placebo-controlled study with patients diagnosed with major depression unresponsive to standard pharmaceutical medications is a significant milestone achievement for Medlab’s research group. We look forward to the independent analysis of the data that will provide important links between the gut bacteria cohort, blood metabolites and mood; and the level of treatment efficacy achieved for depression with a Medlab patented formulation.”

Medlab has indicated that completion of this trial, whilst retaining its statistical relevance, is a key driver for the business as MDC moving forward in managing the company's exposure to COVID and any potential economic impact.

Trials focus on an adjunct to depression treatment which is globally estimated to be \$864 million USD market in 2015 and is expected to reach \$1.2 billion USD by 2024<sup>1</sup>. Overall, the global depression market is estimated to be \$15.6 billion USD, at 2.4% CAGR.<sup>2</sup>

The impact of the trials progressing ahead of expectations marks an important milestone to expanded commercialisation opportunities that drug registration would offer. Medlab would expect results publication, and Doctor/Pharmacist education as well as undertaking heightened dialogue with the TGA to determine next potential steps.

For and behalf of the Board.



Dr Sean Hall  
Managing Director

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)  
**FOR FURTHER** DR SEAN HALL, CEO, MEDLAB CLINICAL  
**INFORMATION:** TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

---

<sup>1</sup> <https://www.researchandmarkets.com/reports/4199131/global-treatment-resistant-depression-market>

<sup>2</sup> <https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html>